

Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Count
1 BRS	L1	2	"20030031682"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 13:46			0
2 BRS	L2	6344	streptococcus adj (pyogenes or aureus or pneumoniae or agalactiae)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:45			0
3 BRS	L3	748	group adj b adj streptococcus	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:46			0
4 BRS	L4	489	group adj a adj streptococcus	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:46			0
5 BRS	L5	201	sp36	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:46			0
6 BRS	L6	692	antigen same (2 or 3 or 4 or 5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:47			0
7 BRS	L7	985	polypeptide same (2 or 3 or 4 or 5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:48			0
8 BRS	L8	1	sp36 same antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:50			0
9 BRS	L9	0	sp36 same antigen	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:51			0
10 BRS	L10	2	sp36 same vaccine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/2 6 15:51			0

=> d his

(FILE 'HOME' ENTERED AT 15:57:06 ON 26 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

15:57:32 ON 26 MAY 2003

L1 4366 S GROUP A STREPTOCOCCUS
L2 5739 S GROUP B STREPTOCOCCUS
L3 76316 S STREPTOCOCCUS (W) (PYROGENES OR AUREUS OR
PNEUMONIAE OR AGALA
L4 83658 S L1 OR L2 OR L3
L5 3720 S L4 (P) ANTIGEN
L6 1135 S L4 (P) PEPTIDE
L7 4763 S L5 OR L6
L8 19 S SP36
L9 6 S L8 (P) ANTIBODY
L10 6 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)
L11 1 S L7 (P) L8
L12 1 S L11 NOT L10

=> log y

FILE 'MEDLINE' ENTERED AT 15:57 ON 26 MAY 2003

FILE 'CAPLUS' ENTERED AT 15:57:32 ON 26 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:57:32 ON 26 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 15:57:32 ON 26 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:57:32 ON 26 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 15:57:32 ON 26 MAY 2003

=> s group a streptococcus
L1 4366 GROUP A STREPTOCOCCUS

=> s group b streptococcus
L2 5739 GROUP B STREPTOCOCCUS

=> s streptococcus (w) (pyrogenes or aureus or pneumoniae or agalactiae)
L3 76316 STREPTOCOCCUS (W) (PYROGENES OR AUREUS OR PNEUMONIAE OR AGALACTI
AE)

=> s l1 or l2 or l3
L4 83658 L1 OR L2 OR L3

=> s l4 (p) antigen
L5 3720 L4 (P) ANTIGEN

=> s l4 (p) peptide
L6 1135 L4 (P) PEPTIDE

=> s l5 or l6
L7 4763 L5 OR L6

=> s sp36
L8 19 SP36

=> s l8 (p) antibody
L9 6 L8 (P) ANTIBODY

=> duplicate remove l9
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L9
L10 6 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

=> d l10 1-6 ibib abs

L10 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:152723 CAPLUS

DOCUMENT NUMBER: 134:206562

TITLE: Homologs of a pneumococcal protein and fragments for
vaccines

INVENTOR(S): Koenig, Scott; Heinrichs, Jon; Johnson, Leslie Sydnor;
Adamou, John E.

PATENT ASSIGNEE(S): Medimmune, Inc., USA

SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2001014421 A1 20010301 WO 2000-US23417 20000825 CU, CZ,
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1210366 A1 20020605 EP 2000-959433 20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003507054 T2 20030225 JP 2001-518750 20000825
US 1999-150750P P 19990825
WO 2000-US23417 W 20000825
PRIORITY APPLN. INFO.:

AB The invention is directed to isolated polypeptides bearing sequence homol. to the ***Sp36*** protein found in pneumococcal organisms, such as Streptococcus pneumoniae. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to ***antibodies*** specific for the disclosed polypeptides and to uses of such ***antibodies*** in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addn., the invention relates to the use of the disclosed polypeptides in compns. and as vaccines and for prophylactic uses such as in vaccination of animals, esp. humans, against a wide variety of streptococcal, staphylococcal and other diseases.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:441653 CAPLUS
DOCUMENT NUMBER: 133:88211
TITLE: Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
Johnson, Leslie S.; Koenig, Scott; Adamou, John E.
INVENTOR(S): Medimmune, Inc., USA
PATENT ASSIGNEE(S): PCT Int. Appl., 70 pp.
SOURCE: CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037105	A2	20000629	WO 1999-US30390	19991221
WO 2000037105	A3	20001109		
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355364	AA	20000629	CA 1999-2355364	19991221
EP 1140157	A2	20011010	EP 1999-967460	19991221
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002532561	T2	20021002	JP 2000-589215	19991221
			US 1998-113048P	19981221
PRIORITY APPLN. INFO.:			WO 1999-US30390	W 19991221

AB A vaccine compn. is disclosed that comprises polypeptides and fragments of polypeptides contg. histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compns.

L10 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:2937 CAPLUS
DOCUMENT NUMBER: 114:2937

TITLE: Measurement of the surfactant apoprotein (***SP36***) by the immunoassay kit using its monoclonal ***antibodies***
AUTHOR(S): Eguchi, Hideshi; Kawase, Atsusi; Kamiya, Kenji; Ogawa, Yunosuke; Hosoda, Kenji
CORPORATE SOURCE: Saitama Med. Sch., Saitama Med. Cent., Japan
SOURCE: Nippon Kaimen Igakkai Zasshi (1989), 20(1-2), 79-82
CODEN: NKIZDR; ISSN: 0288-8262

DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB An immunoassay kit for the detn. of 36 kDa pulmonary surfactant apoprotein (SP36) was prepd. and tested. In this kit, SP36 was sandwiched between PC6 insolubilized on polystyrene beads and peroxidase labeled PE10, and then this pulmonary surfactant specific protein in a small quantity of the tracheal aspirate was detd. accurately within 1 h using a std. spectrophotometer. To test the influence of blood and meconium contamination on the immunoassay kit, blood and meconium was added to the adult tracheal aspirates in various concns. Blood in the tracheal aspirate had no influence on the immunoassay kit in concns. 1:10 to 1:50. In contrast, immunoreaction was depressed by meconium contamination, if the meconium was not removed by centrifugation. Tracheal aspirates were obtained from 8 premature infants with respiratory distress syndrome (RDS), premature infants without RDS and term infants, and the concns. of surfactant specific protein (SP36) were assayed by this enzyme immunoassay kit. Tracheal aspirates obtained from the infants with RDS within the first 24 h after birth showed almost negligible amts. of surfactant. On the other hand, considerable amts. of surfactant were detected in the tracheal aspirates from premature infants without RDS and term infants. The concn. of surfactant specific protein (SP36) rose more than 5 $\mu\text{g/mL}$ around 30-60 h after birth (recovery phase) in these RDS infants. Thus the assay kit was a suitable procedure for the detn. of surfactant apoprotein in the tracheal aspirates of the newborn infants.

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
1988:489224 CAPLUS

ACCESSION NUMBER: 109:89224
DOCUMENT NUMBER: Immunoassay kit for the determination of the pulmonary surfactant apoprotein ***SP36*** with its monoclonal ***antibodies*** in human amniotic fluid

AUTHOR(S): Shimizu, Hiroshi; Kataoka, Kenji; Adachi, Hideaki; Mizumoto, Masahiko; Kuroki, Yoshio; Hagiwara, Masahiro; Fujimoto, Seiichiro; Hosoda, Kenji; Suzuki, Hideaki; Akino, Toyooki

CORPORATE SOURCE: Dep. Biochem., Sapporo Med. Coll., Sapporo, Japan
SOURCE: Igaku no Ayumi (1988), 145(2), 123-4
CODEN: IGAYAY; ISSN: 0367-7826

DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB An assay kit for the detn. of pulmonary surfactant apoprotein of 36 kilodaltons (***SP36***) was developed. ***SP36*** in amniotic fluid could be detd. accurately within 1 h with a std. spectrophotometer by the assay kit. The concn. of ***SP36*** in 67 amniotic fluid samples detd. by the assay kit were well correlated with those detd. by a microplate immunoassay with 2 monoclonal ***antibodies***. This method was simple, rapid, and accurate for the detn. of amniotic fluid ***SP36***.

L10 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
1989:112751 CAPLUS

ACCESSION NUMBER: 110:112751
DOCUMENT NUMBER: Immunohistochemical studies on human pulmonary surfactant apoprotein SP5

AUTHOR(S): Dempo, Kimimaro; Sakauchi, Fumio; Sato, Masaaki; Mori, Michio; Mizumoto, Masahiko; Adachi, Hideaki; Kataoka, Kenji; Akino, Toyooki

CORPORATE SOURCE: Dep. Pathol., Sapporo Med. Coll., Japan
SOURCE: Nippon Kaimen Igakkai Zasshi (1988), 19(1-2), 104-7
CODEN: NKIZDR; ISSN: 0288-8262

DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The immunohistochem. characterization of surfactant protein ***SP36***

and the hydrophobic apoprotein SP5 was compared in human lung specimens. Mouse anti-human SP5 ***antibodies*** recognized human SP5 but not human ***SP36*** and human serum proteins. The anti-human SP5 ***antibodies*** were used for immunohistochem. studies of human lungs by immunoperoxidase staining. In adult lung specimens, the granular reaction products were found in the cytoplasm of some alveolar wall cells which appeared to be alveolar Type II cells, but not either Type I cells or bronchiolar cells. However, this immunoperoxidase staining profile with SP5 ***antibodies*** seemed to be somewhat different from that with ***SP36*** monoclonal ***antibody*** (PE10). This difference in the Type II cell staining between both ***antibodies*** was found more distinctly in fetal lungs and lung carcinomas. Fetal lung sections up to 20 wk gestation showed no pos. staining with both ***antibodies***. In the lung sections of 27.apprx.40 wk gestation, both ***antibodies*** showed pos. reaction. However, PE10 stained more alveolar spaces, but SP5 ***antibodies*** stained more Type II cells. In these cases, one case was PE10 neg., but SP5 ***antibodies*** pos. In lung carcinoma, both ***antibodies*** stained only the cell type of adenocarcinoma differentiation. However, SP5 ***antibodies*** stained more cells of adenocarcinoma than PE10. Although PE10 sometimes stained alveolar spaces, SP5 stained only the cytoplasm of cancer cells.

L10 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1988:160787 BIOSIS

DOCUMENT NUMBER: BA85:84440
TITLE: INTRACELLULAR LOCALIZATION OF PULMONARY SURFACTANT-ASSOCIATED GLYCOPROTEINS SP36.

AUTHOR(S): TAKAHASHI H; KUROKI Y
CORPORATE SOURCE: DEP. INTERN. MED., SAPPORO MED. COLL., JPN.
SOURCE: SAPPORO MED J, (1987) 56 (6), 771-786.
CODEN: SIZSAR. ISSN: 0036-472X.

FILE SEGMENT: BA; OLD
LANGUAGE: Japanese

AB The 36 kDa glycoproteins (***SP36***) are the main apoprotein components in pulmonary surfactant and are known to have structural heterogeneity due to their different carbohydrate chains. The present study was performed to elucidate the relationship between structure and metabolism of the ***SP36***. Human lung tissues were fractionated into six subfractions by discontinuous sucrose density gradient centrifugation. The fractions of human lung, in order of increasing density, consisted of lamellar bodies (Fr. I and II), extracellular surfactant and intracellular small vesicles (Fr. III and IV) and endoplasmic reticulum (Fr. V) as shown by electron microscopy, lipid analysis and marker enzyme assays. Electrophoresis of the proteins in the fractions revealed that the lamellar bodies and endoplasmic reticulum distinctly differed in their protein components of ***SP36***. The former contained 34 kDa protein, while the latter contained 37 kDa proteins as the major ***SP36***. Fr. III and IV contained both proteins with more 34 kDa protein than 37 kDa. By two-dimensional electrophoresis, they were separated to 6-8 isoproteins. The 37 kDa proteins consisted of more acidic proteins and the 34 kDa proteins were more basic proteins. These 34 kDa proteins in all the fractions were stained by the immunoblot method using a monoclonal ***antibody*** (PE 10) to human ***SP36***. When both 34 kDa and 37 kDa proteins were treated by N-glycosidase F, the reaction product was 30 kDa protein which could also be stained by the immunoblot method. These results suggest that the 37 kDa glycoprotein may be primarily synthesized from the 30 kDa core protein in the endoplasmic reticulum of alveolar Type II cells and may be processed to the 34 kDa glycoprotein during the transfer from endoplasmic reticulum to lamellar bodies.

=> d his

(FILE 'HOME' ENTERED AT 15:57:06 ON 26 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 15:57:32 ON 26 MAY 2003

L1 4366 S GROUP A STREPTOCOCCUS
L2 5739 S GROUP B STREPTOCOCCUS
L3 76316 S STREPTOCOCCUS (W) (PYROGENES OR AUREUS OR PNEUMONIAE OR AGALA
L4 83658 S L1 OR L2 OR L3

L5 3720 S L4 (P) ANTIGEN
L6 1135 S L4 (P) PEPTIDE
L7 4763 S L5 OR L6
L8 19 S SP36
L9 6 S L8 (P) ANTIBODY
L10 6 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

=> s 17 (p) 18
L11 1 L7 (P) L8

=> d l11 not l10
L10 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l11 not l10
L12 1 L11 NOT L10

=> d l12 1 ibib abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:215876 CAPLUS

DOCUMENT NUMBER: 134:309427

TITLE: Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus

AUTHOR(S): pneumoniae infection
Wizemann, Theresa M.; Heinrichs, Jon H.; Adamou, John
E.; Erwin, Alice L.; Kunsch, Charles; Choi, Gil H.;
Barash, Steven C.; Rosen, Craig A.; Masure, H. Robert;
Tuomanen, Elaine; Gayle, Anthony; Brewah, Yambasu A.;
Walsh, William; Barren, Philip; Lathigra, Raju;
Hanson, Mark; Langermann, Solomon; Johnson, Syd;
Koenig, Scott

CORPORATE SOURCE: MedImmune, Inc., Gaithersburg, MD, 20878, USA
SOURCE: Infection and Immunity (2001), 69(3), 1593-1598

PUBLISHER: CODEN: INFIBR; ISSN: 0019-9567
DOCUMENT TYPE: American Society for Microbiology

LANGUAGE: Journal

AB English

Microbial targets for protective humoral immunity are typically surface-localized proteins and contain common sequence motifs related to their secretion or surface binding. Exploiting the whole genome sequence of the human bacterial pathogen Streptococcus pneumoniae, the authors identified 130 open reading frames encoding proteins with secretion motifs or similarity to predicted virulence factors. Mice were immunized with 108 of these proteins, and 6 conferred protection against disseminated S. pneumoniae infection. Flow cytometry confirmed the surface localization of several of these targets. Each of the six protective antigens showed broad strain distribution and immunogenicity during human infection. Our results validate the use of a genomic approach for the identification of novel microbial targets that elicit a protective immune response. These new antigens may play a role in the development of improved vaccines against S. pneumoniae.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:57:06 ON 26 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 15:57:32 ON 26 MAY 2003

L1 4366 S GROUP A STREPTOCOCCUS
L2 5739 S GROUP B STREPTOCOCCUS
L3 76316 S STREPTOCOCCUS (W) (PYROGENES OR AUREUS OR PNEUMONIAE OR AGALA
L4 83658 S L1 OR L2 OR L3
L5 3720 S L4 (P) ANTIGEN
L6 1135 S L4 (P) PEPTIDE
L7 4763 S L5 OR L6
L8 19 S SP36
L9 6 S L8 (P) ANTIBODY
L10 6 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

L11 1 S L7 (P) L8
L12 1 S L11 NOT L10

=> log y
COST IN U.S. DOLLARS

SINCE FILE
ENTRY
49.63

TOTAL
SESSION
49.84

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY
-3.91

TOTAL
SESSION
-3.91

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:03:12 ON 26 MAY 2003